Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Emergent BioSolutions Inc.NYSE: EBS
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital declines year over year
Q1 FY2026 other working capital of $14.3M (cash outflow) fell 62.2% year over year, ahead of the -91.8% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at -42.8% a year.
Context
- Other working capital amounted to 1.2% of revenue in FY2025, down 15.1 pp from a year earlier.
- Other working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -62.2% holds above the trailing-twelve-month pace of -91.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (9.2M) USD
- Year-over-year change
- -105.4%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.2M) | -105.4% |
| FY2024 | 2024-12-31 | 170.6M | +384.8% |
| FY2023 | 2023-12-31 | (59.9M) | -22.0% |
| FY2022 | 2022-12-31 | (49.1M) | +20.4% |
| FY2021 | 2021-12-31 | (61.7M) | — |
Other Working Capital vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -91.8% is the 10th highest of 11, against a peer median of +107.0%.
- Other working capital amounts to 2.1% of revenue for EBS, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.81M USD | +281.6% | +137.4% | 7.6% | |
| LTM Mar 2026 | $14.3M USD | -91.8% | -42.8% | 2.1% | |
| LTM Mar 2026 | $13.64M USD | +378.0% | — | — | |
| LTM Mar 2026 | $11.61M USD | +121.2% | — | 20.0% | |
| LTM Mar 2026 | $9.65M USD | -26.2% | -21.0% | — | |
| LTM Mar 2026 | $6.23M USD | -83.9% | — | 1.2% | |
| LTM Mar 2026 | $2.36M USD | +114.8% | -49.7% | 4.7% | |
| LTM Mar 2026 | $804.27K USD | -78.2% | -9.0% | 0.9% | |
| LTM Mar 2026 | $325K USD | -131.2% | +10.5% | 0.1% | |
| LTM Mar 2026 | CA$278K CAD | +109.0% | — | 0.0% | |
| LTM Mar 2026 | $59K USD | +105.0% | +49.7% | — | |
| Peer median (excluding EBS) | — | +107.0% | +0.8% | 1.2% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 230.9M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Depreciation & Amortization | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Deferred Income Tax | 46.9M | (28.6M) | (8.9M) | (5.5M) | (4M) |
| Stock-Based Compensation | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Change in Working Capital | (156.4M) | (2.1M) | (70.3M) | 88.7M | (22.4M) |
| Accounts Receivables | (48.2M) | 118.1M | (21.6M) | (24.4M) | 25.5M |
| Inventory | (44M) | (57.1M) | 600K | (24.5M) | (30.3M) |
| Accounts Payables | (2.5M) | (14M) | 10.6M | (33M) | (8.4M) |
| Other Working Capital | (61.7M) | (49.1M) | (59.9M) | 170.6M | (9.2M) |
| Other Non-Cash Items | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Operating Cash Flow | 321.1M | (34.1M) | (206.3M) | 58.7M | 170.6M |
| Capital Expenditures | (225M) | (115.8M) | (51.6M) | (22.9M) | (13.8M) |
| Acquisitions (Net) | 0 | 0 | 270.2M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (265.5M) | (6.3M) | 148.1M | 83.2M |
| Investing Cash Flow | (225M) | (381.3M) | 212.3M | 125.2M | 69.4M |
| Debt Repayment | (35.9M) | 564.2M | (543.4M) | (198.4M) | (112.5M) |
| Common Stock Issued | 0 | 0 | 8.4M | 9.3M | 2.2M |
| Common Stock Repurchased | (106M) | (82.1M) | 0 | 0 | (24.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 900K | (900K) | (700K) | (900K) | (1.4M) |
| Financing Cash Flow | (141M) | 481.2M | (535.7M) | (190M) | (136.6M) |
| Effect of Forex Changes | (300K) | 500K | (1.2M) | 0 | 100K |
| Net Change in Cash | (45.2M) | 66.3M | (530.9M) | (6.1M) | 103.5M |
| Free Cash Flow | 96.1M | (149.9M) | (257.9M) | 35.8M | 156.8M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.